Galectin Therapeutics (GALT) Earning Somewhat Favorable News Coverage, Report Finds
News stories about Galectin Therapeutics (NASDAQ:GALT) have been trending somewhat positive this week, Accern reports. Accern scores the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Galectin Therapeutics earned a news impact score of 0.20 on Accern’s scale. Accern also gave media headlines about the company an impact score of 48.2784003060803 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
GALT has been the topic of several analyst reports. ValuEngine downgraded Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Roth Capital started coverage on Galectin Therapeutics in a research report on Thursday, October 19th. They issued a “buy” rating and a $8.00 target price for the company. Finally, Seaport Global Securities reiterated a “buy” rating and issued a $5.00 target price on shares of Galectin Therapeutics in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $4.63.
Galectin Therapeutics (GALT) opened at $2.70 on Friday. Galectin Therapeutics has a 12-month low of $0.81 and a 12-month high of $3.68.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. research analysts forecast that Galectin Therapeutics will post -0.55 EPS for the current year.
Galectin Therapeutics Company Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.
Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.